Outcomes based MRD status. (A) PFS based on ASC sample MRD status, (B) CIR/nonrelapse mortality based on ASC sample MRD status, (C) OS based on ASC sample MRD status, (D) PFS according to 90-day post-ASCT landmark analysis based on plasma MRD status. (Patients were included in the landmark analysis if they were alive and relapse-free 90 days after ASCT, and they had a plasma sample available for MRD testing 90 [±30] days after ASCT). CIR, cumulative incidence of relapse.